Casdin Capital, LLC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 201 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.

Quarter-by-quarter ownership
Casdin Capital, LLC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$4,140,000
-37.1%
1,000,000
+81.8%
0.35%
+109.6%
Q2 2021$6,584,000
-4.5%
550,0000.0%0.17%
-18.5%
Q1 2021$6,892,000
-59.1%
550,000
-49.1%
0.20%
-58.9%
Q4 2020$16,853,000
+65.1%
1,080,0000.0%0.50%
+9.2%
Q3 2020$10,206,000
-21.7%
1,080,000
-25.8%
0.46%
-40.8%
Q2 2020$13,037,000
+40.7%
1,455,0000.0%0.77%
-21.5%
Q1 2020$9,268,000
-23.9%
1,455,0000.0%0.98%
-12.1%
Q4 2019$12,178,000
-99.9%
1,455,0000.0%1.12%
-17.8%
Q3 2019$13,167,750,000
-20.1%
1,455,000
-4.9%
1.36%
-11.6%
Q2 2019$16,478,100,000
+159835.0%
1,530,000
+41.7%
1.54%
+36.2%
Q1 2019$10,303,000
-16.9%
1,080,0000.0%1.13%
-46.6%
Q4 2018$12,398,000
-63.4%
1,080,000
-46.0%
2.12%
-48.5%
Q3 2018$33,900,000
+70.5%
2,000,000
+42.9%
4.12%
+48.2%
Q2 2018$19,880,000
-25.3%
1,400,0000.0%2.78%
-40.6%
Q1 2018$26,600,000
+15.9%
1,400,0000.0%4.68%
-16.3%
Q4 2017$22,960,000
+9.3%
1,400,0000.0%5.59%
-5.7%
Q3 2017$21,000,000
+70.5%
1,400,0000.0%5.93%
+30.1%
Q2 2017$12,320,000
+178.7%
1,400,000
+64.7%
4.56%
+74.8%
Q1 2017$4,420,000850,0002.61%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Golden State Equity Partners 154,360$897,0000.45%
Rhenman & Partners Asset Management AB 761,429$4,424,0000.44%
Lombard Odier Asset Management (Switzerland) SA 860,702$5,001,0000.39%
WASATCH ADVISORS LP 10,576,997$61,452,0000.30%
Rokos Capital Management LLP 977,663$5,861,0000.27%
KLK CAPITAL MANAGEMENT LLC 44,323$258,0000.26%
Long Focus Capital Management, LLC 340,000$1,975,0000.25%
Vanguard Capital Wealth Advisors 33,380$193,0000.14%
Fort Sheridan Advisors LLC 73,978$430,0000.13%
Delphia (USA) Inc. 20,983$122,0000.09%
View complete list of SANGAMO THERAPEUTICS INC shareholders